These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 12101426

  • 1. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W.
    Oncogene; 2002 Jul 18; 21(31):4863-71. PubMed ID: 12101426
    [Abstract] [Full Text] [Related]

  • 2. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y.
    Nat Genet; 2000 Mar 18; 24(3):245-50. PubMed ID: 10700176
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.
    Ishizaki Y, Ikeda S, Fujimori M, Shimizu Y, Kurihara T, Itamoto T, Kikuchi A, Okajima M, Asahara T.
    Int J Oncol; 2004 May 18; 24(5):1077-83. PubMed ID: 15067328
    [Abstract] [Full Text] [Related]

  • 4. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
    Kim YD, Park CH, Kim HS, Choi SK, Rew JS, Kim DY, Koh YS, Jeung KW, Lee KH, Lee JS, Juhng SW, Lee JH.
    J Gastroenterol Hepatol; 2008 Jan 18; 23(1):110-8. PubMed ID: 18171349
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
    Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P, Perret C.
    Oncogene; 2007 Feb 01; 26(5):774-80. PubMed ID: 16964294
    [Abstract] [Full Text] [Related]

  • 6. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
    Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA.
    Oncogene; 2000 Jan 27; 19(4):498-504. PubMed ID: 10698519
    [Abstract] [Full Text] [Related]

  • 7. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
    Wu R, Zhai Y, Fearon ER, Cho KR.
    Cancer Res; 2001 Nov 15; 61(22):8247-55. PubMed ID: 11719457
    [Abstract] [Full Text] [Related]

  • 8. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
    Koch A, Weber N, Waha A, Hartmann W, Denkhaus D, Behrens J, Birchmeier W, von Schweinitz D, Pietsch T.
    J Pathol; 2004 Dec 15; 204(5):546-54. PubMed ID: 15538750
    [Abstract] [Full Text] [Related]

  • 9. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.
    Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, Eilers R, Dienes HP, Schirmacher P.
    J Pathol; 2003 Oct 15; 201(2):250-9. PubMed ID: 14517842
    [Abstract] [Full Text] [Related]

  • 10. Beta-catenin and cyclin D1 expression in human hepatocellular carcinoma.
    Ueta T, Ikeguchi M, Hirooka Y, Kaibara N, Terada T.
    Oncol Rep; 2002 Oct 15; 9(6):1197-203. PubMed ID: 12375019
    [Abstract] [Full Text] [Related]

  • 11. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis.
    Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY, Park CK.
    Liver Int; 2005 Feb 15; 25(1):70-6. PubMed ID: 15698401
    [Abstract] [Full Text] [Related]

  • 12. Abnormalities of the APC/beta-catenin pathway in endometrial cancer.
    Moreno-Bueno G, Hardisson D, Sánchez C, Sarrió D, Cassia R, García-Rostán G, Prat J, Guo M, Herman JG, Matías-Guiu X, Esteller M, Palacios J.
    Oncogene; 2002 Nov 14; 21(52):7981-90. PubMed ID: 12439748
    [Abstract] [Full Text] [Related]

  • 13. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam.
    Anna CH, Sills RC, Foley JF, Stockton PS, Ton TV, Devereux TR.
    Cancer Res; 2000 Jun 01; 60(11):2864-8. PubMed ID: 10850429
    [Abstract] [Full Text] [Related]

  • 14. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway.
    Torbenson M, Lee JH, Choti M, Gage W, Abraham SC, Montgomery E, Boitnott J, Wu TT.
    Mod Pathol; 2002 Mar 01; 15(3):189-96. PubMed ID: 11904335
    [Abstract] [Full Text] [Related]

  • 15. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.
    Chen YW, Jeng YM, Yeh SH, Chen PJ.
    Hepatology; 2002 Oct 01; 36(4 Pt 1):927-35. PubMed ID: 12297840
    [Abstract] [Full Text] [Related]

  • 16. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.
    Buendia MA.
    Med Pediatr Oncol; 2002 Nov 01; 39(5):530-5. PubMed ID: 12228912
    [Abstract] [Full Text] [Related]

  • 17. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
    Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA.
    Hepatology; 2002 Sep 01; 36(3):692-701. PubMed ID: 12198663
    [Abstract] [Full Text] [Related]

  • 18. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors.
    Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, Garcia PD, Randazzo FM, Escobedo J, Fantl WJ, Williams LT.
    Proc Natl Acad Sci U S A; 2001 Dec 18; 98(26):14973-8. PubMed ID: 11752446
    [Abstract] [Full Text] [Related]

  • 19. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity.
    Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, Zucman-Rossi J.
    Oncogene; 1999 Jul 08; 18(27):4044-6. PubMed ID: 10435629
    [Abstract] [Full Text] [Related]

  • 20. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.
    Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T.
    Cancer Res; 1999 Jan 15; 59(2):269-73. PubMed ID: 9927029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.